RXADVANCE
2 Park Central Drive
Southborough, MA 01772

FIRST TIME GENERIC APPROVAL

Brand Name	Truvada®
Generic Name	emtricitabine-tenofovir
Drug Manufacturer	Teva Pharmaceuticals USA

New Drug Approval

TYPE OF CLINICAL UPDATE

First Time Generic Approval

FDA APPROVAL DATE

June 8, 2017

LAUNCH DATE

October 2, 2020

REVIEW DESIGNATION

Standard

TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 090894

DISPENSING RESTRICTIONS

Open Distribution

Overview

INDICATION FOR USE

It is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated:

- In combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg.

HIV-1 PrEP:

- Indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating Truvada® for HIV-1 PrEP.

MECHANISMS OF ACTION

Emtricitabine: A synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate (FTC-TP), which inhibits the activity of the HIV-1 reverse transcriptase (RT) by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. FTC-TP is a weak inhibitor of mammalian DNA polymerases α, β, ε and mitochondrial DNA polymerase γ.

FIRST TIME GENERIC APPROVAL

Tenofovir Disoproxil Fumarate: An acyclic nucleoside phosphonate diester analog of adenosine monophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate (TFV-DP), which inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5'- triphosphate and, after incorporation into DNA, by DNA chain termination. TFV-DP is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.

DOSE FORM AND STRENGTH

Tablets: 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate, respectively.

DOSE & ADMINISTRATION

Testing: Prior to or when initiating emtricitabine and tenofovir disoproxil fumarate tablets test for hepatitis B virus infection. Prior to initiation and during use of emtricitabine and tenofovir disoproxil fumarate tablets, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all individuals. In individuals with chronic kidney disease, also assess serum phosphorus.

HIV-1 Screening: Screen all individuals for HIV-1 infection immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP and at least once every 3 months while taking emtricitabine and tenofovir disoproxil fumarate tablets, and upon diagnosis of any other sexually transmitted infections (STIs).

Treatment of HIV-1 Infection:

- Recommended dosage in adults and pediatric patients weighing at least 35 kg: One emtricitabine and tenofovir disoproxil fumarate tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.
- Recommended dosage in pediatric patients weighing at least 17 kg: One emtricitabine and tenofovir disoproxil fumarate low-strength tablet (100 mg/150 mg, 133 mg/ 200 mg, or 167 mg/250 mg based on body weight) once daily taken orally with or without food.
- Recommended dosage in renally impaired HIV-1 infected adult patients:
    - Creatinine clearance (CrCl) 30–49 mL/min: 1 tablet every 48 hours.
    - CrCl below 30 mL/min or hemodialysis: emtricitabine and tenofovir disoproxil fumarate tablets are not recommended.

HIV-1 Pre-Exposure Prophylaxis (PrEP):

- Recommended dosage in HIV-1 uninfected adults and adolescents weighing at least 35 kg: One emtricitabine and tenofovir disoproxil fumarate tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken orally with or without food.
- Recommended dosage in renally impaired HIV-uninfected individuals: emtricitabine and tenofovir disoproxil fumarate tablets are not recommended in HIV-uninfected individuals if CrCl is below 60 mL/min.